The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95154
Title:
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.
Authors:
Sprangers, M; Groenvold, M; Arraras, J; Franklin, J; Te Velde, A; Muller, M; Franzini, L; Williams, A; De Haes, H; Hopwood, Penelope; Cull, A; Aaronson, N
Abstract:
PURPOSE: To construct a breast cancer-specific quality-of-life questionnaire (QLQ) module to be used in conjunction with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and to test its reliability and validity cross-culturally. PATIENTS AND METHODS: Module construction took place after the EORTC guidelines for module development. The module--the QLQ-BR23--consists of 23 items covering symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. This module was tested in 170 Dutch, 168 Spanish, and 158 American cancer patients at two points in time. The timing for the Dutch and Spanish patients was before and during treatment with radiotherapy or chemotherapy. For the American patients, the questionnaire was administered at admission at the breast clinic and 3 months after the first assessment. RESULTS: Multitrait scaling analysis confirmed the hypothesized structure of four of the five scales. Cronbach's alpha coefficients were, in general, lowest in Spain (range; .46 to .94) and highest in the United States (range; .70 to .91). On the basis of known-groups comparisons, selective scales distinguished clearly between patients differing in disease stage, previous surgery, performance status, and treatment modality, according to expectation. Additionally, selective scales detected change over time as a function of changes in performance status and treatment-induced change. CONCLUSION: These results lend support to the clinical and cross-cultural validity of the QLQ-BR23 as a supplementary questionnaire for assessing specific quality-of-life issues relevant to patients with breast cancer.
Affiliation:
Netherlands Cancer Institute, Amsterdam, The Netherlands. M.A.Sprangers@AMC.UVA.NL
Citation:
The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. 1996, 14 (10):2756-68 J. Clin. Oncol.
Journal:
Journal of Clinical Oncology
Issue Date:
Oct-1996
URI:
http://hdl.handle.net/10541/95154
PubMed ID:
8874337
Type:
Article
Language:
en
ISSN:
0732-183X
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSprangers, Men
dc.contributor.authorGroenvold, Men
dc.contributor.authorArraras, Jen
dc.contributor.authorFranklin, Jen
dc.contributor.authorTe Velde, Aen
dc.contributor.authorMuller, Men
dc.contributor.authorFranzini, Len
dc.contributor.authorWilliams, Aen
dc.contributor.authorDe Haes, Hen
dc.contributor.authorHopwood, Penelopeen
dc.contributor.authorCull, Aen
dc.contributor.authorAaronson, Nen
dc.date.accessioned2010-03-29T10:32:20Z-
dc.date.available2010-03-29T10:32:20Z-
dc.date.issued1996-10-
dc.identifier.citationThe European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. 1996, 14 (10):2756-68 J. Clin. Oncol.en
dc.identifier.issn0732-183X-
dc.identifier.pmid8874337-
dc.identifier.urihttp://hdl.handle.net/10541/95154-
dc.description.abstractPURPOSE: To construct a breast cancer-specific quality-of-life questionnaire (QLQ) module to be used in conjunction with the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and to test its reliability and validity cross-culturally. PATIENTS AND METHODS: Module construction took place after the EORTC guidelines for module development. The module--the QLQ-BR23--consists of 23 items covering symptoms and side effects related to different treatment modalities, body image, sexuality, and future perspective. This module was tested in 170 Dutch, 168 Spanish, and 158 American cancer patients at two points in time. The timing for the Dutch and Spanish patients was before and during treatment with radiotherapy or chemotherapy. For the American patients, the questionnaire was administered at admission at the breast clinic and 3 months after the first assessment. RESULTS: Multitrait scaling analysis confirmed the hypothesized structure of four of the five scales. Cronbach's alpha coefficients were, in general, lowest in Spain (range; .46 to .94) and highest in the United States (range; .70 to .91). On the basis of known-groups comparisons, selective scales distinguished clearly between patients differing in disease stage, previous surgery, performance status, and treatment modality, according to expectation. Additionally, selective scales detected change over time as a function of changes in performance status and treatment-induced change. CONCLUSION: These results lend support to the clinical and cross-cultural validity of the QLQ-BR23 as a supplementary questionnaire for assessing specific quality-of-life issues relevant to patients with breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshBreast Neoplasms-
dc.subject.meshCross-Cultural Comparison-
dc.subject.meshFeasibility Studies-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshLanguage-
dc.subject.meshMiddle Aged-
dc.subject.meshPatient Participation-
dc.subject.meshQuality of Life-
dc.subject.meshQuestionnaires-
dc.subject.meshReproducibility of Results-
dc.titleThe European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.en
dc.typeArticleen
dc.contributor.departmentNetherlands Cancer Institute, Amsterdam, The Netherlands. M.A.Sprangers@AMC.UVA.NLen
dc.identifier.journalJournal of Clinical Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.